260 related articles for article (PubMed ID: 23451143)
21. Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study.
Oikonomopoulou K; Scorilas A; Michael IP; Grass L; Soosaipillai A; Rosen B; Murphy J; Diamandis EP
Tumour Biol; 2006; 27(2):104-14. PubMed ID: 16557045
[TBL] [Abstract][Full Text] [Related]
22. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
[TBL] [Abstract][Full Text] [Related]
23. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.
Xi Z; Kaern J; Davidson B; Klokk TI; Risberg B; Tropé C; Saatcioglu F
Gynecol Oncol; 2004 Jul; 94(1):80-5. PubMed ID: 15262123
[TBL] [Abstract][Full Text] [Related]
24. Metastasis of ovarian cancer is mediated by kallikrein related peptidases.
Dong Y; Loessner D; Irving-Rodgers H; Obermair A; Nicklin JL; Clements JA
Clin Exp Metastasis; 2014 Jan; 31(1):135-47. PubMed ID: 24043563
[TBL] [Abstract][Full Text] [Related]
25. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer.
Loessner D; Goettig P; Preis S; Felber J; Bronger H; Clements JA; Dorn J; Magdolen V
Expert Opin Ther Targets; 2018 Sep; 22(9):745-763. PubMed ID: 30114962
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of kallikrein-related peptidase-4 in oral cancer.
Papagerakis P; Pannone G; Zheng LI; Athanassiou-Papaefthymiou M; Yamakoshi Y; McGuff HS; Shkeir O; Ghirtis K; Papagerakis S
Anticancer Res; 2015 Apr; 35(4):1861-6. PubMed ID: 25862839
[TBL] [Abstract][Full Text] [Related]
27. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
Wang P; Magdolen V; Seidl C; Dorn J; Drecoll E; Kotzsch M; Yang F; Schmitt M; Schilling O; Rockstroh A; Clements JA; Loessner D
Br J Cancer; 2018 Oct; 119(7):1-9. PubMed ID: 30287916
[TBL] [Abstract][Full Text] [Related]
28. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
29. Modeling the effect of ascites-induced compression on ovarian cancer multicellular aggregates.
Klymenko Y; Wates RB; Weiss-Bilka H; Lombard R; Liu Y; Campbell L; Kim O; Wagner D; Ravosa MJ; Stack MS
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30254133
[TBL] [Abstract][Full Text] [Related]
30. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
Tadić V; Zhang W; Brozovic A
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
[TBL] [Abstract][Full Text] [Related]
31. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
[TBL] [Abstract][Full Text] [Related]
32. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.
Lee JM; Mhawech-Fauceglia P; Lee N; Parsanian LC; Lin YG; Gayther SA; Lawrenson K
Lab Invest; 2013 May; 93(5):528-42. PubMed ID: 23459371
[TBL] [Abstract][Full Text] [Related]
33. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.
Burleson KM; Casey RC; Skubitz KM; Pambuccian SE; Oegema TR; Skubitz AP
Gynecol Oncol; 2004 Apr; 93(1):170-81. PubMed ID: 15047232
[TBL] [Abstract][Full Text] [Related]
34. Ca
Ohya S; Kajikuri J; Endo K; Kito H; Elboray EE; Suzuki T
Cancer Sci; 2021 Sep; 112(9):3769-3783. PubMed ID: 34181803
[TBL] [Abstract][Full Text] [Related]
35. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.
Kim KH; Xie Y; Tytler EM; Woessner R; Mor G; Alvero AB
J Transl Med; 2009 Jul; 7():63. PubMed ID: 19619321
[TBL] [Abstract][Full Text] [Related]
36. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.
Gratio V; Beaufort N; Seiz L; Maier J; Virca GD; Debela M; Grebenchtchikov N; Magdolen V; Darmoul D
Am J Pathol; 2010 Mar; 176(3):1452-61. PubMed ID: 20056842
[TBL] [Abstract][Full Text] [Related]
37. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
[TBL] [Abstract][Full Text] [Related]
38. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer.
Puiffe ML; Le Page C; Filali-Mouhim A; Zietarska M; Ouellet V; Tonin PN; Chevrette M; Provencher DM; Mes-Masson AM
Neoplasia; 2007 Oct; 9(10):820-9. PubMed ID: 17971902
[TBL] [Abstract][Full Text] [Related]
39. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
Tang MK; Zhou HY; Yam JW; Wong AS
Neoplasia; 2010 Feb; 12(2):128-38. PubMed ID: 20126471
[TBL] [Abstract][Full Text] [Related]
40. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
